secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2026-09-28T12:00:26+00:00
Accession:  0001493152-26-044451
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Matinas BioPharma effects 1-for-15 reverse stock split on Sept 28, 2026; CUSIP changes to 576810 402
--------------------------------------------------------------------------------

- Certificate of Amendment filed with Delaware on Sept 25, 2026; split effective 12:01 a.m. ET Sept 28, 2026, with NYSE American trading on a split-adjusted basis at the open.
- Every 15 shares of $0.0001 par value common stock converted into 1 share; no fractional shares issued, with holders receiving a proportional cash payment instead.
- Par value and authorized share count unchanged; outstanding options, warrants and convertible preferred stock were proportionally adjusted.
- Stockholders approved the amendment at the June 23, 2025 annual meeting; the Board authorized the filing on Sept 16, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315226044451/0001493152-26-044451-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315226044451/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-044451

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer